Clinical Trials on Epilepsy With Partial On-set Seizures in Spain

Total 21 results

Neuroelectrics Corporation

Recruiting

Pivotal-Safety and Therapeutic Measures of tDCS in Patients With Refractory Focal Epilepsy

Epilepsy | Seizures | Refractory Epilepsy | Epilepsy, Tonic-Clonic | Epilepsy in Children | Seizures, Focal | Focal Seizure

Spain, United States, France, Belgium
Pfizer

Completed

To Evaluate Long-Term Safety and Efficacy of Pregabalin in Patients With Partial Seizures.

Seizure Disorder, Partial

Spain, France, Italy, Australia, United Kingdom, Germany, Belgium, Netherlands, Austria, Sweden, Finland, South Africa, Switzerland
Pfizer

Completed

Evaluation of Long-Term Safety and Efficacy of Pregabalin in Patients With Partial Seizures.

Seizure Disorder, Partial

Australia, Spain, Portugal, United Kingdom, Canada, Belgium, Germany, Poland, Netherlands, Austria
Johnson & Johnson Pharmaceutical Research & Development...

Completed

Topiramate as Adjunctive Therapy in Infants 1-24 Months for the Control of Partial Onset Seizures

Epilepsy | Seizures | Partial Seizure Disorder

United States, Australia, France, Belgium, Taiwan, Spain, Argentina, Poland, India, Ukraine, Finland, Korea, Republic of, Russian Federation, Chile, Thailand, Hungary, Israel, New Zealand, Canada, Mexico, Norway, Netherlands, South...
Bial - Portela C S.A.

Completed

Eslicarbazepine Acetate (BIA 2 093) as Therapy for Refractory Partial Seizures in Children

Partial Epilepsy in Children and Adolescents

United Kingdom, Spain, Serbia, Italy, Austria, Bosnia and Herzegovina, Croatia, Czechia, France, Germany, Hungary, Malaysia, Moldova, Republic of, Philippines, Poland, Portugal, Romania, Russian Federation, Slovakia, Taiwan, Ukr...
Pfizer's Upjohn has merged with Mylan to form Viatris...

Completed

A 12-Month Study To Evaluate The Safety And Tolerability Of Pregabalin As Add-On Therapy In Pediatric Subjects 1 Month To 16 Years Of Age With Partial Onset Seizures And Pediatric And Adult Subjects 5 To 65 Years Of Age With Primary Generalized Tonic-Clonic Seizures

Epilepsy, Partial Seizures | Epilepsy, Primary Generalized Tonic-Clonic Seizures

United States, Korea, Republic of, Taiwan, Lebanon, Singapore, Malaysia, China, Spain, Bulgaria, Czechia, United Kingdom, Israel, Russian Federation, France, Belarus, Belgium, Bosnia and Herzegovina, Germany, Greece, Hungary, India and more
Pfizer

Completed

Pregabalin Open-Label Extension Trial in Patients With Partial Seizures

Epilepsies, Partial | Epilepsy, Complex Partial

Spain, France, Canada, Germany, Italy, Lithuania, Austria, United Kingdom
Eisai Limited

Completed

A Study to Investigate Dosage, Effectiveness, and Safety of Perampanel When Used as First Add-on Therapy in Participants >=12 Years With Partial Onset Seizures With or Without Secondary Generalization or With Primary Generalized Tonic-Clonic Seizures Associated With Idiopathic Generalized Epilepsy

Idiopathic Generalized Epilepsy | Partial Onset Seizures | Generalised Tonic-Clonic Seizures

France, Spain, Italy, Denmark, Germany, Portugal, Russian Federation
UCB Pharma

Completed

Assess Safety and Efficacy of Lacosamide in Patients With Partial Seizures

Epilepsy

France, Poland, United Kingdom, Germany, Spain, Finland, Australia, Russian Federation, Hungary, Lithuania, Sweden, Czechia, Croatia
Eisai Inc.

Completed

Efficacy and Safety of Adjunctive Zonisamide in Paediatric Partial Onset Seizures (CATZ Study)

Epilepsy; Paediatric Partial Onset Seizures

Belgium, France, Italy, Spain, Estonia, Hungary, Poland, Ukraine, Latvia
Xenon Pharmaceuticals Inc.
Worldwide Clinical Trials

Enrolling by invitation

An Open-label Study of XEN1101 in Epilepsy (X-TOLE4)

Focal Epilepsy | Tonic-Clonic Seizures

Spain, United States, Canada, Poland
SK Life Science, Inc.

Recruiting

Safety and Efficacy Study of Cenobamate in Pediatric Subjects 2-17 Years of Age With Partial-onset (Focal) Seizures

Partial Epilepsy

United States, Spain, Korea, Republic of, Germany, Australia, Poland, Hungary
UCB Pharma

Completed

Trial to Assess Lacosamide as the First add-on Anti-epileptic Drug Treatment in Patients With Partial-onset Seizures

Partial Epilepsies

United States, Austria, Bulgaria, Czechia, Denmark, Finland, France, Greece, Italy, Mexico, Romania, Russian Federation, Spain, Switzerland, Turkey
SK Life Science, Inc.

Completed

A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Trial of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures

Partial Epilepsy

Australia, United States, Korea, Republic of, Germany, Hungary, Serbia, Bulgaria, Czechia, France, Israel, Poland, Romania, Spain, Thailand, Ukraine
SK Life Science, Inc.

Completed

Safety and Pharmacokinetic Study of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures

Partial Epilepsy

United States, Spain, Korea, Republic of, Serbia, Germany, Bulgaria, Argentina, Australia, Chile, Czechia, Hungary, Mexico, Poland, Russian Federation, Sweden, Thailand, Ukraine
Eisai Inc.

Completed

Assessing The Long-Term Safety And To Explore The Long-Term Efficacy Of Zonisamide As Monotherapy In Newly Diagnosed Partial Seizures

Epilepsy

Greece, Italy, Spain, Sweden, Korea, Republic of, Germany, Australia, France, Switzerland, Slovakia, Poland, Taiwan, Hungary, Serbia, India, United Kingdom, Denmark, Russian Federation, South Africa, Montenegro
UCB Pharma

Completed

A Study of Brivaracetam in Subjects With Partial Onset Seizures

Epilepsy, Focal

France, Poland, United Kingdom, Belgium, Germany, Spain, Czech Republic, Finland, Netherlands
UCB Biopharma S.P.R.L.
Pharm Research Associates (UK) Ltd.

Completed

Study to Look at How Effective Briviact is as add-on Treatment for Patients With Epilepsy With Partial Onset Seizures (BASE)

Epilepsy With POS With or Without Secondary Generalization

Denmark, Germany, Hungary, Ireland, Italy, Netherlands, Norway, Spain, United Kingdom
Eisai Inc.

Recruiting

A Study to Evaluate Efficacy and Safety of Perampanel Administered as an Adjunctive Therapy in Pediatric Participants With Childhood Epilepsy

Partial-onset Seizures | Pediatric Epileptic Syndrome

United States, Spain, France, Belgium, Czechia, Denmark, Germany
UCB Pharma

Completed

Post-Authorization Safety Study to Assess the Safety of Vimpat as add-on Therapy in Patients With Partial-onset Seizures (PASS)

Epilepsies, Partial

France, Germany, United Kingdom, Spain, Netherlands
Eisai Inc.

Available

An Extended Access Program (EAP) for Perampanel

Lennox Gastaut Syndrome | Primary Generalized Tonic-Clonic or Partial Onset Seizures

Belgium, Chile, Estonia, Hungary, Latvia, Lithuania, Poland, Spain

Clinical Trials on Epilepsy With Partial On-set Seizures in Spain

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Türkiye

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations